X
[{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics Announces Abstract Presentation at the 2020 European Renal Association","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Emcure Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emcure Pharma Launches Generic Drug for Hyperphosphatemia in Chronic Kidney Disease Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase IV","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase IV"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Real-World Setting Study Shows Velphoro Effective in CKD-HP Management","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase IV"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"R\u00e9nibus Therapeutics to Present Phase 1b Data on RBT-1 at Acute Kidney Injury & Continuous Renal Replacement Therapy 2021 Conference","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Renibus Therapeutics Announces Appointment of Frank Stonebanks as CEO and $35 Million Series A Funding","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Renibus Therapeutics Announces $47 Million Financing to Advance Lead Program RBT-1 Through Pivotal Phase 3 Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Juniper Point","pharmaFlowCategory":"D","amount":"$72.0 million","upfrontCash":"Undisclosed","newsHeadline":"Renibus Therapeutics Announces Final Close of Upsized Series B Financing, Bringing Total Round to $72 Million","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics Announces Positive Interim Data from RBT-1 Phase 2 Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Vifor Fresenius Medical Care Renal Pharma","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VFMCRP Announces U.S. Court Upholds Validity of Velphoro\u00ae Patent","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase IV"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics Announces Positive 30-Day Topline Data from RBT-1 Phase 2 Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics Announces Breakthrough Therapy Designation from US FDA for RBT-1 for the Reduction in Risk of Post-Operative Complications in Patients Undergoing Cardiothoracic Surgery","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1 to Reduce Post-operative Complications After Cardiothoracic Surgery","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Announces Publication of Results from Phase 2 Study Evaluating RBT-1 as a Pre-Conditioning Agent to Reduce Post-Operative Complications Following Cardiothoracic Surgery","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals for Iron Sucrose
Filters
Companies By Therapeutic Area
Details:
RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways which is currently under phase 3 clinical trials for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Lead Product(s):
Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: RBT-1
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 09, 2024
Details:
RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Lead Product(s):
Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: RBT-1
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 25, 2023
Details:
The proceeds will advance RBT-1 through a pivotal Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery. RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways.
Lead Product(s):
Iron Sucrose ,Stannus Protoporphyrin
Therapeutic Area: Nephrology
Product Name: RBT-1
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Juniper Point
Deal Size: $72.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
September 12, 2023
Details:
The proceeds will advance RBT-1 (stannic protoporfin/iron sucrose), a potent inducer of anti-inflammatory, antioxidant and iron scavenging pathways, through Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery.
Lead Product(s):
Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: RBT-1
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: $47.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
July 18, 2023
Details:
RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways that is advancing toward for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Lead Product(s):
Iron Sucrose ,Stannus Protoporphyrin
Therapeutic Area: Nephrology
Product Name: RBT-1
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 11, 2023
Details:
RBT-1 (Iron sucrose), treated patients demonstrated a highly significant increase in anti-inflammatory and antioxidant biomarkers of cytoprotective preconditioning. The biomarkers assessed were interleukin-10, heme oxygenase-1 and ferritin.
Lead Product(s):
Iron Sucrose ,Stannus Protoporphyrin
Therapeutic Area: Nephrology
Product Name: RBT-1
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 05, 2023
Vifor Fresenius Medical Care Renal Pharma
Details:
Velphoro (sucroferric oxyhydroxide) ® is a non-calcium, iron-based, chewable phosphate binder approved for the control of phosphate levels in the blood of adults with chronic kidney disease on dialysis.
Lead Product(s):
Iron Sucrose
Therapeutic Area: Nephrology
Product Name: Velphoro
Highest Development Status: Phase IV
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Teva Pharmaceutical Industries
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 22, 2022
Details:
RBT-1 (Iron Sucrose) met primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning; positive data supports the potential for RBT-1 to impact clinical outcomes in cardiothoracic surgery patients.
Lead Product(s):
Iron Sucrose ,Stannus Protoporphyrin
Therapeutic Area: Nephrology
Product Name: RBT-1
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 15, 2022
Details:
Proceeds from the recent financing will be used to advance Renibus’ pipeline, including the company’s lead candidates, RBT-1 for prevention of acute kidney injury (AKI), currently in a large (126 patients), randomized, double-blind study in AKI in a cardiac surgery setting.
Lead Product(s):
Iron Sucrose ,Stannus Protoporphyrin
Therapeutic Area: Nephrology
Product Name: RBT-1
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: $35.0 million
Upfront Cash: Undisclosed
Deal Type: Series A Financing
February 15, 2022
Details:
This Phase 2 study will evaluate the efficacy of RBT-1 in generating a preconditioning response as measured by a composite of biomarkers in subjects who are at risk for AKI following cardiac surgery.
Lead Product(s):
Iron Sucrose ,Stannus Protoporphyrin
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: RBT-1
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 11, 2021